SCHEMBL2687516

SCHEMBL2687516

CC(=O)NCc1nc2cc(-c3nc4cc(Cl)ccc4o3)ccc2n1C1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 4/20 0.48
SENP7 Q9BQF6 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
LMNA P02545 2/20 0.47
THRB P10828 2/20 0.47
PARP3 Q9Y6F1 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
AHR P35869 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CETP P11597 3/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687130 0.83 CASP3 (0.61) CASP3SENP7NPC1RAB9APOLB
SCHEMBL2686940 0.81 KDM4E (0.51) CASP3SENP7NPC1RAB9APOLB
SCHEMBL2688580 0.80 KDM4E (0.54) CASP3SENP7NPC1RAB9APOLB
SCHEMBL2689825 0.80 PARP3 (0.42) CASP3SENP7NPC1RAB9APOLB
SCHEMBL2687597 0.79 RPS6KB1 (0.47) CASP3SENP7NPC1RAB9APOLB
SCHEMBL10219866 0.79 HPSE (0.45) CASP3SENP7NPC1RAB9APOLB
SCHEMBL10219625 0.78 MAPT (0.39) NPC1RAB9APOLBSMN1; SMN2KDM4E
SCHEMBL2687370 0.77 RPS6KB1 (0.45) CASP3SENP7NPC1RAB9APOLB
SCHEMBL2687744 0.77 SMN1; SMN2 (0.38) NPC1RAB9APOLBSMN1; SMN2KDM4E
SCHEMBL10219827 0.76 HPSE (0.49) CASP3SENP7NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
WO-2010137349-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS 住友化学株式会社 (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 CASP3 1060/4885SENP7 2939/4885NPC1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.